These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 37686200)
1. Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients. Leest PV; Janning M; Rifaela N; Azpurua MLA; Kropidlowski J; Loges S; Lozano N; Sartori A; Irwin D; Lamy PJ; Hiltermann TJN; Groen HJM; Pantel K; Kempen LCV; Wikman H; Schuuring E Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686200 [TBL] [Abstract][Full Text] [Related]
2. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA. Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455 [TBL] [Abstract][Full Text] [Related]
3. The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Kulasinghe A; O'Leary C; Monkman J; Bharti V; Irwin D; Dutta S; Richard DJ; Hughes B; Ladwa R; O'Byrne K Lung Cancer; 2021 Oct; 160():73-77. PubMed ID: 34455214 [TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC. Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases. Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550 [TBL] [Abstract][Full Text] [Related]
6. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078 [TBL] [Abstract][Full Text] [Related]
7. Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel. Ryan DJ; Toomey S; Smyth R; Madden SF; Workman J; Cummins R; Sheehan K; Fay J; Naidoo J; Breathnach OS; Morris PG; Grogan L; O'Brien ME; Sulaiman I; Hennessy BT; Morgan RK Lung Cancer; 2022 Jun; 168():67-73. PubMed ID: 35526313 [TBL] [Abstract][Full Text] [Related]
8. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma. Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897 [TBL] [Abstract][Full Text] [Related]
9. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence. Gassa A; Fassunke J; Schueten S; Kuhlmann L; Scherer M; Qien J; Zhao Y; Michel M; Loeser H; Wolf J; Buettner R; Doerr F; Heldwein M; Hagmeyer L; Frank K; Merkelbach-Bruse S; Quaas A; Bruns C; Hekmat K; Weiss J; Wahlers T; Alakus H Lung Cancer; 2021 Jan; 151():91-96. PubMed ID: 33257044 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. Belloum Y; Janning M; Mohme M; Simon R; Kropidlowski J; Sartori A; Irwin D; Westphal M; Lamszus K; Loges S; Riethdorf S; Pantel K; Wikman H Cells; 2020 Oct; 9(11):. PubMed ID: 33105541 [TBL] [Abstract][Full Text] [Related]
11. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC). Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593 [TBL] [Abstract][Full Text] [Related]
12. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study. Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582 [TBL] [Abstract][Full Text] [Related]
14. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
15. Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. Gray ES; Witkowski T; Pereira M; Calapre L; Herron K; Irwin D; Chapman B; Khattak MA; Raleigh J; Hatzimihalis A; Cebon J; Sandhu S; McArthur GA; Millward M; Ziman M; Dobrovic A; Wong SQ J Mol Diagn; 2019 May; 21(3):418-426. PubMed ID: 30731208 [TBL] [Abstract][Full Text] [Related]
16. Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA. Stitz R; Buder A; Silye R; Baumgartner B; Pühringer F; Filipits M; Oberndorfer E; Heitzer E Exp Mol Pathol; 2021 Dec; 123():104685. PubMed ID: 34560086 [TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912 [TBL] [Abstract][Full Text] [Related]
18. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595 [TBL] [Abstract][Full Text] [Related]
19. Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients. Fan F; Jiang G; Lv J; Wang H; Li W; Liu C; Zhao Y; Zhang Z; Du H; Zhang Z; Li X; Li WC Cancer Med; 2024 Oct; 13(19):e70078. PubMed ID: 39385536 [TBL] [Abstract][Full Text] [Related]
20. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]